Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Pharmacotherapy of depression: a historical analysis.

Ban TA.

J Neural Transm (Vienna). 2001;108(6):707-16.

PMID:
11478422
2.

Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.

Thomas SJ, Shin M, McInnis MG, Bostwick JR.

Pharmacotherapy. 2015 Apr;35(4):433-49. doi: 10.1002/phar.1576. Review.

3.

[Efficacy of atypical antipsychotics in depressive syndromes].

Quintin P, Thomas P.

Encephale. 2004 Nov-Dec;30(6):583-9. Review. French.

PMID:
15738862
4.

The transdermal delivery system of monoamine oxidase inhibitors.

VanDenBerg CM.

J Clin Psychiatry. 2012;73 Suppl 1:25-30. doi: 10.4088/JCP.11096su1c.04. Review.

5.

Monoamine neurocircuitry in depression and strategies for new treatments.

Hamon M, Blier P.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:54-63. doi: 10.1016/j.pnpbp.2013.04.009. Epub 2013 Apr 19. Review.

PMID:
23602950
6.

History and therapeutic use of MAO-A inhibitors: a historical perspective of mao-a inhibitors as antidepressant drug.

Yáñez M, Padín JF, Arranz-Tagarro JA, Camiña M, Laguna R.

Curr Top Med Chem. 2012;12(20):2275-82. Review.

PMID:
23231399
7.

Invited review: the evolution of antidepressant mechanisms.

Slattery DA, Hudson AL, Nutt DJ.

Fundam Clin Pharmacol. 2004 Feb;18(1):1-21. Review.

PMID:
14748749
8.

The dual-action hypothesis: does pharmacology matter?

Shelton RC.

J Clin Psychiatry. 2004;65 Suppl 17:5-10. Review.

9.

Reversible monoamine oxidase-A inhibitors in resistant major depression.

Nolen WA, Hoencamp E, Bouvy PF, Haffmans PM.

Clin Neuropharmacol. 1993;16 Suppl 2:S69-76. Review.

PMID:
8313400
10.

Translating the evidence on atypical depression into clinical practice.

Hyman Rapaport M.

J Clin Psychiatry. 2007;68 Suppl 3:31-6. Review.

11.

Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today.

López-Muñoz F, Alamo C.

Curr Pharm Des. 2009;15(14):1563-86. Review.

PMID:
19442174
13.

The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects.

Dell'Osso B, Palazzo MC, Oldani L, Altamura AC.

CNS Neurosci Ther. 2011 Dec;17(6):723-32. doi: 10.1111/j.1755-5949.2010.00217.x. Epub 2010 Dec 14. Review.

PMID:
21155988
14.

Translating the evidence on atypical depression into clinical practice.

Rapaport MH, Thase ME.

J Clin Psychiatry. 2007 Apr;68(4):e11. Review.

15.

Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review.

Ruhé HG, Huyser J, Swinkels JA, Schene AH.

J Clin Psychiatry. 2006 Dec;67(12):1836-55. Review.

PMID:
17194261
16.

Potentials of curcumin as an antidepressant.

Kulkarni S, Dhir A, Akula KK.

ScientificWorldJournal. 2009 Nov 1;9:1233-41. doi: 10.1100/tsw.2009.137. Review.

17.

Antidepressants for smoking cessation.

Hughes JR, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000031. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD000031.

PMID:
17253443
18.

Moclobemide: therapeutic use and clinical studies.

Bonnet U.

CNS Drug Rev. 2003 Spring;9(1):97-140. Review.

19.

Antidepressant drug development: Focus on triple monoamine reuptake inhibition.

Lane RM.

J Psychopharmacol. 2015 May;29(5):526-44. doi: 10.1177/0269881114553252. Epub 2014 Oct 14. Review.

PMID:
25315829
20.

Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.

Prins J, Olivier B, Korte SM.

Expert Opin Investig Drugs. 2011 Aug;20(8):1107-30. doi: 10.1517/13543784.2011.594039. Epub 2011 Jun 20. Review.

PMID:
21682663

Supplemental Content

Support Center